Table 4 Summary of included studies
Study | Type of work | Location | Sample Size / Cohort | IG type | Study period | Study Design/Analysis |
|---|---|---|---|---|---|---|
Alcantara et al. (2021) [32] | Journal article | Single site in Toronto, Ontario | 34 patients with generalized MG | IVIG & SCIG | 2015–2020 | Retrospective cohort study |
Arnold et al. (2020) [50] | Journal article | Canada-wide | 74 patients with ITP | IVIG vs eltrombopag | 2013–2019 | Clinical trial (randomized, open-label)(Bridging ITP Trial) |
Bourque et al. (2016) [31] | Journal article | Single site in Ottawa, Ontario | 9 patients with MG | IVIG & SCIG | 2015–2016 | Retrospective cohort study |
Brownlee et al. (2022) [48] | Journal article | Single site in Ottawa, Montreal | 10 patients with PID or SID who did not tolerate the side effects of 20% SCIG | SCIG | 2018–2020 | Prospective cohort |
Fu et al. (2018) [35]a | Journal article | Single site in Toronto, Ontario | 57 PID patients | SCIG & IVIG | Study published in 2018- | Cost savings study |
Gerth et al. (2014) [34]a | Journal article | N/A | PID/SID patients | IVIG & SCIG | N/A | Cost savings simulation study |
Hsia et al. (2015) [27] | Journal article | Two hospitals in Ontario | 383 adult patients with ITP | IVIG | 2003–2012 | Retrospective audit |
Jutras et al. (2021) [26] | Journal article | Single site in Montréal Québec | 172 critically ill pediatric patients | IVIG | 2013–2018 | Retrospective cohort study |
Kaur et al. (2022) [51] | Journal article | Canada-wide | 74 patients with ITP | IVIG vs eltrombopag | 2013–2019 | Cost-effectiveness analysis of data from Bridging ITP Trial |
Keith et al. (2022) [46]a | Journal article | 6 centers across Canada (except Québec) | 125 Patients with PID or SID | SCIG | 2018–2020 | Phase 4, non-interventional, prospective, single-arm study |
Kobayashi et al. (2022) [47]a | Journal article | Multi-national, including Canada | 102 patients with PID | SCIG | 238 weeks follow-up duration. Dates were not mentioned | Secondary analysis of data from previous single-arm phase 3 trials |
Liu et al. (2019) [28] | Journal article | Single site in Toronto, Ontario | 40 patients with ITP | IVIG | 2014 | Audit |
Mallick et al. (2022) [41]a | Journal article | Canada-wide | 296 Patients with PID or SID | SCIG & IVIG | 2020–2021 | Survey Study |
Murphy et al. (2019) [17] | Journal article | Four sites in Ottawa, Ontario | 2629 patients | IVIG | 2007–2016 | Trend Analysis |
Reid et al. (2014) [37] | Journal article | Referral centers or community hospitals in Ontario | 169 patients who were on hospital-based IG replacement therapy | IVIG & SCIG | – | Survey using questionnaire |
Ritchie et al. (2022) [36]a | Journal article | Alberta, Province-wide | 7890 adult and pediatric patients who used IG products | SCIG & IVIG | 2012–2019 | Retrospective population-based cohort |
Shih et al. (2017) [9] | Journal article | Four sites in Ontario | 178 adult patients | IVIG | 2014 | Audit |
Sholapur et al. (2016) [38] | Journal article | Single site in Ontario | 12 ITP patients | IVIG | Study published in 2016- | Cross-sectional study |
Suleman et al. (2019) [33]a | Journal article | Single site in Ottawa, Ontario | 19 patients with immune-mediated neurological disorders | IVIG & SCIG | 2010–2016 | Retrospective cohort study |
Sultan et al. (2017) [39]a | Journal article | Single site in Montreal, Québec | 60 children with PID | SCIG | Study published in 2017- | Cross-sectional study |
Tran et al. (2023) [29] | Journal article | Three hospitals in British Columbia | 114 patients with SID | SCIG & IVIG | 2018–2019 | Retrospective cohort/audit |
Walter et al (2014) [45] | Journal article | Manitoba, province-wide | 62 patients with PID | SCIG | 2007–2018 | Retrospective |
Abadeh et al. (2023) [49] | Conference abstract | Ontario, multicentre | 108 patients with SID | IVIG/SCIG | 2020–2022 | Cross-sectional |
Furlan et al. (2016) [52] | Conference abstract | Ontario | 32 patients who received IVIG and 38 patients treated with plasma exchange | IVIG | 2007–2010 | Cost-minimization analysis |
Mallon et al. (2016) [43] | Conference abstract | Alberta, multicentre | 8 patients with MG | SCIG | – | Clinical trial |
Shabani-Rad et al. (2018) [30] | Conference abstract | Calgary, Alberta | IVIG recipients | IVIG | 2017 | Cross-sectional |
Siddiqi et al. (2018) [44] | Conference abstract | Alberta, multicentre | 822 patients with MG | SCIG | – | Clinical trial |
Streu et al (2016) [42] | Conference abstract | Manitoba, single centre | 53 patients with CLL | SCIG | Two year period | Prospective |
Zhou et al. (2021) [40] | Conference abstract | Ontario, single centre | Adult patients receiving IVIG for Inflammatory Myositis | IVIG/SCIG | – | Survey |